Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Bret Jensen Investing Group Leader Follow Summary Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers. Despite the meteoric share run, PRAX retains significant upside, justifying a small investment, with covered calls offering an attractive entry strategy. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » quantic69/iStock via Getty Images Shares of CNS drug concern Praxis Precision Medicines, Inc. ( PRAX ) have rallied over 1,000% since April 2025, led by ulixacaltamide’s stunning clinical reversal and approvable results from relutrigine. Ulixacaltamide delivered a p-score of <0.0001 after the Data Monitoring Committee This article was written by Bret Jensen 58.66K Followers Follow Bret Jensen has been investing since the 1980s. He has been writing for Real Money Pro and Seeking Alpha since 2010. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary, and a portfolio update every weekend. Learn More. Analyst’s Disclosure: I/we have a beneficial long position in the shares of PRAX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.